脑出血强化降压治疗:随机对照试验的系统评价与更新Meta分析
该系统评价与Meta分析纳入11项随机对照试验共13625例脑出血患者(强化组6755例),比较强化降压(目标<140 mmHg)与标准管理。强化降压组不良功能结局(mRS 3-6分)显著减少(RR 0.93,95%CI 0.90-0.96,p<0.01),良好功能结局(mRS 0-2分)增加(RR 1.09,95%CI 1.01-1.18,p=0.03),全因死亡(RR 0.86,95%CI 0.79-0.94,p<0.01)和显著血肿扩大(RR 0.83,95%CI 0.73-0.95,p<0.01)均显著降低。亚组分析(血压目标阈值、随机化时间窗<6小时 vs ≥6小时、目标类型基于收缩压 vs 基于平均动脉压)未发现显著交互作用。作者认为强化降压可能改善功能结局并降低死亡、残疾和血肿扩大风险。
要点
- 纳入11项RCT共13625例脑出血患者,强化降压目标<140 mmHg。
- 强化降压组不良功能结局(mRS 3-6分)显著减少:RR 0.93(95%CI 0.90-0.96,p<0.01)。
- 强化降压组全因死亡显著降低:RR 0.86(95%CI 0.79-0.94,p<0.01)。
- 强化降压组显著血肿扩大显著减少:RR 0.83(95%CI 0.73-0.95,p<0.01)。
- 亚组分析(血压目标阈值、随机化时间窗<6小时 vs ≥6小时、目标类型)未发现显著交互作用。
适用人群与场景
- 脑出血患者,纳入比较强化降压(目标<140 mmHg)与标准管理的随机对照试验。
处置流程与药物剂量
- 强化降压目标为<140 mmHg。
研究设计与关键结果
- 研究类型:系统评价与更新Meta分析,纳入11项随机对照试验,共13625例患者(强化组6755例)。
- 干预与对照:强化降压(目标<140 mmHg)vs 标准管理。
- 主要终点:不良功能结局(mRS 3-6分)强化组RR 0.93(95%CI 0.90-0.96,p<0.01);良好功能结局(mRS 0-2分)强化组RR 1.09(95%CI 1.01-1.18,p=0.03)。
- 关键次要终点:全因死亡强化组RR 0.86(95%CI 0.79-0.94,p<0.01);显著血肿扩大强化组RR 0.83(95%CI 0.73-0.95,p<0.01)。
- 亚组分析:血压目标阈值、随机化时间窗(<6小时 vs ≥6小时)、血压目标类型(基于收缩压 vs 基于平均动脉压)均未发现显著交互作用。
证据类型、等级与局限
- 证据类型:系统评价与更新Meta分析,纳入随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,脑出血强化降压可能改善功能结局并降低死亡、残疾和血肿扩大风险,支持其在急性管理中的潜在作用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Intracerebral hemorrhage (ICH) is often associated with elevated blood pressure (BP), increasing the risk of persistent and recurrent hemorrhage, disability, and death. Previous studies have reported conflicting results regarding BP management, particularly concerning treatment timing and optimal targets. The aim of this review was to perform a systematic review and meta-analysis comparing intensive BP lowering with standard management in patients with ICH.
METHODS: PubMed, Embase, and Cochrane Library databases were searched for randomized controlled trials (RCTs) comparing intensive BP lowering (target < 140 mm Hg) with standard management in patients with ICH. Outcomes included good functional outcome (modified Rankin scale [mRS] score 0-2), poor functional outcome (mRS score 3-6), all-cause mortality, and substantial hematoma enlargement. Subgroup analyses assessed (1) BP target thresholds, (2) randomization window (< 6 h vs. ≥ 6 h from symptom onset), and (3) BP target type (systolic blood pressure based vs. mean arterial pressure based). All analyses were conducted based on risk ratios (RR) and 95% confidence intervals (CIs) using a random-effects model.
RESULTS: Eleven RCTs (13,625 patients; 6,755 in the intensive group) were included. Intensive BP lowering was associated with a significant reduction in poor functional outcome (mRS score 3-6; RR 0.93, 95% CI 0.90-0.96; p < 0.01) and an increase in good functional outcome (mRS score 0-2; RR 1.09, 95% CI 1.01-1.18; p = 0.03). All-cause mortality (RR 0.86, 95% CI 0.79-0.94; p < 0.01) and substantial hematoma enlargement (RR 0.83, 95% CI 0.73-0.95; p < 0.01) were also significantly lower in the intensive group. The subgroup analyses revealed no significant interactions.
CONCLUSIONS: These findings suggest that intensive BP lowering in ICH might be associated with improved functional outcomes and lower risks of death, disability, and hematoma enlargement, supporting its potential role in acute management.
参考来源
- Reginato PH, Mantovani GP, Furtado da Silva Castro V, et al. Intensive Blood Pressure Lowering for Intracerebral Hemorrhage: A Systematic Review and Updated Meta-analysis of Randomized Controlled Trials. Neurocrit Care. 2025. PMID: 40739079. doi:10.1007/s12028-025-02325-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。